ESC Textbook of Thrombosis
-10%
portes grátis
ESC Textbook of Thrombosis
Moliterno, David; Kristensen, Steen; De Caterina, Raffaele
Oxford University Press
10/2023
400
Dura
Inglês
9780192869227
15 a 20 dias
Descrição não disponível.
1: Raffaele De Caterina, David J. Moliterno, and Steen Dalby Kristensen: Introduction
Section 1: Pathophysiology of thrombosis
2: Lina Badimon and Gemma Vilahur: Arterial thrombosis: Pathophysiological background
3: Marcello Di Nisio, Nicola Potere, Harry R. Buller, and Nick van Es: Venous thrombosis and thromboembolism: Pathophysiological background
4: Peter Calvert, Nicola Tidbury, and Gregory Y. H. Lip: Thrombosis & thromboembolism in atrial fibrillation: Pathophysiological background
5: Tobias Geisler: Thrombosis on foreign surfaces and devices
Section 2: Clinical pharmacology of antithrombotic drugs
6: Carlo Patrono and Bianca Rocca: Aspirin
7: Manan Pareek and Deepak L. Bhatt: Platelet P2Y12 inhibitors
8: Luis Ortega-Paz and Dominick Angiolillo: Dipyridamole, cilostazol, GP IIb/IIIa inhibitors, and PAR-1 antagonists
9: Renske Olie and Hugo ten Cate: Heparins, fondaparinux, hirudin, bivalirudin, argatroban and danaparoid
10: Freek W.A. Verheugt and Marc Brouwer: Vitamin K antagonists
11: Alex Benz and Stefan Hohnloser: Dabigatran
12: Lars C. Wallentin, Agneta Siegbahn, Peter Svensson, and Hakan Wallen: Oral factor Xa (FXa) inhibitors
13: James C. Fredenburgh and Jeffrey I. Weitz: Forthcoming oral factor XIa and FXIIa inhibitors
14: Peter R Sinnaeve and Frans Van de Werf: Thrombolytic therapy and ancillary antithrombotic therapies
Section 3: Therapeutic strategies
15: Raffaele De Caterina, Paul M Ridker, and Erica Michelotti: Antithrombotic strategies in primary cardiovascular prevention
16: Antonio Greco and Davide Capodanno: Antithrombotic strategies in patients undergoing elective percutaneous coronary interventions and in chronic coronary syndromes without interventions
17: William A. E. Parker, Raffaele De Caterina, David J. Moliterno, Steen Dalby Kristensen and Robert F. Storey: Antithrombotic therapy in ST-elevation acute myocardial infarction and non-ST elevation acute coronary syndromes
18: Naoki Misumida, Mohamad Alkhouli, and David J. Moliterno: Anti-thrombotic therapy for patients with prosthetic valves and during structural percutaneous interventions
19: Hans Christoph Diener, Graeme J. Hankey, and John W. Eikelboom: Antithrombotic therapies in ischaemic stroke
20: Jens Erik Nielsen-Kudsk, Kasper Korsholm, Asger Andersen, and Erik Lerkevang Grove: Antithrombotic therapy in patients with patent foramen ovale (PFO), PFO closure, left ventricular mural thrombus, atrial thrombus, and catheter-related thrombosis
21: Raffaele De Caterina and Rossella Marcucci: Atrial fibrillation: current and forthcoming antithrombotic therapies
22: Chaozer Er, Walter Ageno, and Ander Cohen: Venous thromboembolism: prophylaxis and treatment
23: Lars C. Wallentin, Ziad Hijazi, Gorav Bartra, and Johan Lindbaeck: Biomarker-based risk stratification in cardiovascular disease
Section 4: Special situations
24: Vittorio Pengo and Gentian Denas: Antithrombotic therapies in inherited or acquired thrombophilia
25: Roxana Mehran, Alessandro Spirito, George Dangas, and David Cao: Prevention and treatment of bleeding related to antithrombotic drug treatment
26: Michael Maeng, Steen Dalby Kristensen, and Jolanta M. Siller-Matula: Management of patients treated with antithrombotic drugs undergoing surgery
27: Alexander C Fanaroff, Renato D Lopes, John H Alexander: Antithrombotic therapy in patients with atrial fibrillation and recent coronary stenting, with or without an acute coronary syndrome
28: Stefan Agewall, Vanessa Roldan, and Francisco Marin: Prevention and treatment of venous and arterial thrombosis in patients with specific conditions: diabetes, renal insufficiency, thrombophilia and pregnancy
29: Steven P. Dunn, Craig J. Beavers, and David J. Moliterno: Antithrombotic agents and drug-drug interactions
30: Jur ten Berg, Dirk Sibbning, Wout W.A. van den Broek, and Konstantinos D. Rizas: Personalised antithrombotic therapy: Measuring individual variation and monitoring
31: Serge Korjian, Yazan Daaboul, and C. Michael Gibson: Drug development, clinical trials, and regulatory requirements
Section 1: Pathophysiology of thrombosis
2: Lina Badimon and Gemma Vilahur: Arterial thrombosis: Pathophysiological background
3: Marcello Di Nisio, Nicola Potere, Harry R. Buller, and Nick van Es: Venous thrombosis and thromboembolism: Pathophysiological background
4: Peter Calvert, Nicola Tidbury, and Gregory Y. H. Lip: Thrombosis & thromboembolism in atrial fibrillation: Pathophysiological background
5: Tobias Geisler: Thrombosis on foreign surfaces and devices
Section 2: Clinical pharmacology of antithrombotic drugs
6: Carlo Patrono and Bianca Rocca: Aspirin
7: Manan Pareek and Deepak L. Bhatt: Platelet P2Y12 inhibitors
8: Luis Ortega-Paz and Dominick Angiolillo: Dipyridamole, cilostazol, GP IIb/IIIa inhibitors, and PAR-1 antagonists
9: Renske Olie and Hugo ten Cate: Heparins, fondaparinux, hirudin, bivalirudin, argatroban and danaparoid
10: Freek W.A. Verheugt and Marc Brouwer: Vitamin K antagonists
11: Alex Benz and Stefan Hohnloser: Dabigatran
12: Lars C. Wallentin, Agneta Siegbahn, Peter Svensson, and Hakan Wallen: Oral factor Xa (FXa) inhibitors
13: James C. Fredenburgh and Jeffrey I. Weitz: Forthcoming oral factor XIa and FXIIa inhibitors
14: Peter R Sinnaeve and Frans Van de Werf: Thrombolytic therapy and ancillary antithrombotic therapies
Section 3: Therapeutic strategies
15: Raffaele De Caterina, Paul M Ridker, and Erica Michelotti: Antithrombotic strategies in primary cardiovascular prevention
16: Antonio Greco and Davide Capodanno: Antithrombotic strategies in patients undergoing elective percutaneous coronary interventions and in chronic coronary syndromes without interventions
17: William A. E. Parker, Raffaele De Caterina, David J. Moliterno, Steen Dalby Kristensen and Robert F. Storey: Antithrombotic therapy in ST-elevation acute myocardial infarction and non-ST elevation acute coronary syndromes
18: Naoki Misumida, Mohamad Alkhouli, and David J. Moliterno: Anti-thrombotic therapy for patients with prosthetic valves and during structural percutaneous interventions
19: Hans Christoph Diener, Graeme J. Hankey, and John W. Eikelboom: Antithrombotic therapies in ischaemic stroke
20: Jens Erik Nielsen-Kudsk, Kasper Korsholm, Asger Andersen, and Erik Lerkevang Grove: Antithrombotic therapy in patients with patent foramen ovale (PFO), PFO closure, left ventricular mural thrombus, atrial thrombus, and catheter-related thrombosis
21: Raffaele De Caterina and Rossella Marcucci: Atrial fibrillation: current and forthcoming antithrombotic therapies
22: Chaozer Er, Walter Ageno, and Ander Cohen: Venous thromboembolism: prophylaxis and treatment
23: Lars C. Wallentin, Ziad Hijazi, Gorav Bartra, and Johan Lindbaeck: Biomarker-based risk stratification in cardiovascular disease
Section 4: Special situations
24: Vittorio Pengo and Gentian Denas: Antithrombotic therapies in inherited or acquired thrombophilia
25: Roxana Mehran, Alessandro Spirito, George Dangas, and David Cao: Prevention and treatment of bleeding related to antithrombotic drug treatment
26: Michael Maeng, Steen Dalby Kristensen, and Jolanta M. Siller-Matula: Management of patients treated with antithrombotic drugs undergoing surgery
27: Alexander C Fanaroff, Renato D Lopes, John H Alexander: Antithrombotic therapy in patients with atrial fibrillation and recent coronary stenting, with or without an acute coronary syndrome
28: Stefan Agewall, Vanessa Roldan, and Francisco Marin: Prevention and treatment of venous and arterial thrombosis in patients with specific conditions: diabetes, renal insufficiency, thrombophilia and pregnancy
29: Steven P. Dunn, Craig J. Beavers, and David J. Moliterno: Antithrombotic agents and drug-drug interactions
30: Jur ten Berg, Dirk Sibbning, Wout W.A. van den Broek, and Konstantinos D. Rizas: Personalised antithrombotic therapy: Measuring individual variation and monitoring
31: Serge Korjian, Yazan Daaboul, and C. Michael Gibson: Drug development, clinical trials, and regulatory requirements
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
1: Raffaele De Caterina, David J. Moliterno, and Steen Dalby Kristensen: Introduction
Section 1: Pathophysiology of thrombosis
2: Lina Badimon and Gemma Vilahur: Arterial thrombosis: Pathophysiological background
3: Marcello Di Nisio, Nicola Potere, Harry R. Buller, and Nick van Es: Venous thrombosis and thromboembolism: Pathophysiological background
4: Peter Calvert, Nicola Tidbury, and Gregory Y. H. Lip: Thrombosis & thromboembolism in atrial fibrillation: Pathophysiological background
5: Tobias Geisler: Thrombosis on foreign surfaces and devices
Section 2: Clinical pharmacology of antithrombotic drugs
6: Carlo Patrono and Bianca Rocca: Aspirin
7: Manan Pareek and Deepak L. Bhatt: Platelet P2Y12 inhibitors
8: Luis Ortega-Paz and Dominick Angiolillo: Dipyridamole, cilostazol, GP IIb/IIIa inhibitors, and PAR-1 antagonists
9: Renske Olie and Hugo ten Cate: Heparins, fondaparinux, hirudin, bivalirudin, argatroban and danaparoid
10: Freek W.A. Verheugt and Marc Brouwer: Vitamin K antagonists
11: Alex Benz and Stefan Hohnloser: Dabigatran
12: Lars C. Wallentin, Agneta Siegbahn, Peter Svensson, and Hakan Wallen: Oral factor Xa (FXa) inhibitors
13: James C. Fredenburgh and Jeffrey I. Weitz: Forthcoming oral factor XIa and FXIIa inhibitors
14: Peter R Sinnaeve and Frans Van de Werf: Thrombolytic therapy and ancillary antithrombotic therapies
Section 3: Therapeutic strategies
15: Raffaele De Caterina, Paul M Ridker, and Erica Michelotti: Antithrombotic strategies in primary cardiovascular prevention
16: Antonio Greco and Davide Capodanno: Antithrombotic strategies in patients undergoing elective percutaneous coronary interventions and in chronic coronary syndromes without interventions
17: William A. E. Parker, Raffaele De Caterina, David J. Moliterno, Steen Dalby Kristensen and Robert F. Storey: Antithrombotic therapy in ST-elevation acute myocardial infarction and non-ST elevation acute coronary syndromes
18: Naoki Misumida, Mohamad Alkhouli, and David J. Moliterno: Anti-thrombotic therapy for patients with prosthetic valves and during structural percutaneous interventions
19: Hans Christoph Diener, Graeme J. Hankey, and John W. Eikelboom: Antithrombotic therapies in ischaemic stroke
20: Jens Erik Nielsen-Kudsk, Kasper Korsholm, Asger Andersen, and Erik Lerkevang Grove: Antithrombotic therapy in patients with patent foramen ovale (PFO), PFO closure, left ventricular mural thrombus, atrial thrombus, and catheter-related thrombosis
21: Raffaele De Caterina and Rossella Marcucci: Atrial fibrillation: current and forthcoming antithrombotic therapies
22: Chaozer Er, Walter Ageno, and Ander Cohen: Venous thromboembolism: prophylaxis and treatment
23: Lars C. Wallentin, Ziad Hijazi, Gorav Bartra, and Johan Lindbaeck: Biomarker-based risk stratification in cardiovascular disease
Section 4: Special situations
24: Vittorio Pengo and Gentian Denas: Antithrombotic therapies in inherited or acquired thrombophilia
25: Roxana Mehran, Alessandro Spirito, George Dangas, and David Cao: Prevention and treatment of bleeding related to antithrombotic drug treatment
26: Michael Maeng, Steen Dalby Kristensen, and Jolanta M. Siller-Matula: Management of patients treated with antithrombotic drugs undergoing surgery
27: Alexander C Fanaroff, Renato D Lopes, John H Alexander: Antithrombotic therapy in patients with atrial fibrillation and recent coronary stenting, with or without an acute coronary syndrome
28: Stefan Agewall, Vanessa Roldan, and Francisco Marin: Prevention and treatment of venous and arterial thrombosis in patients with specific conditions: diabetes, renal insufficiency, thrombophilia and pregnancy
29: Steven P. Dunn, Craig J. Beavers, and David J. Moliterno: Antithrombotic agents and drug-drug interactions
30: Jur ten Berg, Dirk Sibbning, Wout W.A. van den Broek, and Konstantinos D. Rizas: Personalised antithrombotic therapy: Measuring individual variation and monitoring
31: Serge Korjian, Yazan Daaboul, and C. Michael Gibson: Drug development, clinical trials, and regulatory requirements
Section 1: Pathophysiology of thrombosis
2: Lina Badimon and Gemma Vilahur: Arterial thrombosis: Pathophysiological background
3: Marcello Di Nisio, Nicola Potere, Harry R. Buller, and Nick van Es: Venous thrombosis and thromboembolism: Pathophysiological background
4: Peter Calvert, Nicola Tidbury, and Gregory Y. H. Lip: Thrombosis & thromboembolism in atrial fibrillation: Pathophysiological background
5: Tobias Geisler: Thrombosis on foreign surfaces and devices
Section 2: Clinical pharmacology of antithrombotic drugs
6: Carlo Patrono and Bianca Rocca: Aspirin
7: Manan Pareek and Deepak L. Bhatt: Platelet P2Y12 inhibitors
8: Luis Ortega-Paz and Dominick Angiolillo: Dipyridamole, cilostazol, GP IIb/IIIa inhibitors, and PAR-1 antagonists
9: Renske Olie and Hugo ten Cate: Heparins, fondaparinux, hirudin, bivalirudin, argatroban and danaparoid
10: Freek W.A. Verheugt and Marc Brouwer: Vitamin K antagonists
11: Alex Benz and Stefan Hohnloser: Dabigatran
12: Lars C. Wallentin, Agneta Siegbahn, Peter Svensson, and Hakan Wallen: Oral factor Xa (FXa) inhibitors
13: James C. Fredenburgh and Jeffrey I. Weitz: Forthcoming oral factor XIa and FXIIa inhibitors
14: Peter R Sinnaeve and Frans Van de Werf: Thrombolytic therapy and ancillary antithrombotic therapies
Section 3: Therapeutic strategies
15: Raffaele De Caterina, Paul M Ridker, and Erica Michelotti: Antithrombotic strategies in primary cardiovascular prevention
16: Antonio Greco and Davide Capodanno: Antithrombotic strategies in patients undergoing elective percutaneous coronary interventions and in chronic coronary syndromes without interventions
17: William A. E. Parker, Raffaele De Caterina, David J. Moliterno, Steen Dalby Kristensen and Robert F. Storey: Antithrombotic therapy in ST-elevation acute myocardial infarction and non-ST elevation acute coronary syndromes
18: Naoki Misumida, Mohamad Alkhouli, and David J. Moliterno: Anti-thrombotic therapy for patients with prosthetic valves and during structural percutaneous interventions
19: Hans Christoph Diener, Graeme J. Hankey, and John W. Eikelboom: Antithrombotic therapies in ischaemic stroke
20: Jens Erik Nielsen-Kudsk, Kasper Korsholm, Asger Andersen, and Erik Lerkevang Grove: Antithrombotic therapy in patients with patent foramen ovale (PFO), PFO closure, left ventricular mural thrombus, atrial thrombus, and catheter-related thrombosis
21: Raffaele De Caterina and Rossella Marcucci: Atrial fibrillation: current and forthcoming antithrombotic therapies
22: Chaozer Er, Walter Ageno, and Ander Cohen: Venous thromboembolism: prophylaxis and treatment
23: Lars C. Wallentin, Ziad Hijazi, Gorav Bartra, and Johan Lindbaeck: Biomarker-based risk stratification in cardiovascular disease
Section 4: Special situations
24: Vittorio Pengo and Gentian Denas: Antithrombotic therapies in inherited or acquired thrombophilia
25: Roxana Mehran, Alessandro Spirito, George Dangas, and David Cao: Prevention and treatment of bleeding related to antithrombotic drug treatment
26: Michael Maeng, Steen Dalby Kristensen, and Jolanta M. Siller-Matula: Management of patients treated with antithrombotic drugs undergoing surgery
27: Alexander C Fanaroff, Renato D Lopes, John H Alexander: Antithrombotic therapy in patients with atrial fibrillation and recent coronary stenting, with or without an acute coronary syndrome
28: Stefan Agewall, Vanessa Roldan, and Francisco Marin: Prevention and treatment of venous and arterial thrombosis in patients with specific conditions: diabetes, renal insufficiency, thrombophilia and pregnancy
29: Steven P. Dunn, Craig J. Beavers, and David J. Moliterno: Antithrombotic agents and drug-drug interactions
30: Jur ten Berg, Dirk Sibbning, Wout W.A. van den Broek, and Konstantinos D. Rizas: Personalised antithrombotic therapy: Measuring individual variation and monitoring
31: Serge Korjian, Yazan Daaboul, and C. Michael Gibson: Drug development, clinical trials, and regulatory requirements
Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.
